Pompe Disease Market to Grow at a CAGR of 6.5% from 2025 to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Pompe Disease Market?

The pompe disease market size has experienced consistent growth in recent years. It is projected to increase from $1.74 billion in 2024 to $1.8 billion in 2025, achieving a compound annual growth rate (CAGR) of 3.3%. Historically, this expansion has been driven by factors such as enhanced awareness and diagnosis, orphan drug status and incentives, international collaborations and research initiatives, and the efforts of patient advocacy and support groups.

The pompe disease market is projected to experience robust growth in the upcoming years. It is anticipated to expand to $2.31 billion by 2029, reflecting a compound annual growth rate (CAGR) of 6.5%. The expansion during this forecast period stems from continuous research and development efforts, the broadening of newborn screening programs, advancements in gene therapy, escalating global investment in rare diseases, patient-focused drug development, the proliferation of clinical trials and research initiatives, and the market’s emphasis on personalized medicine strategies. Key trends for the forecast period include product innovation, technological progress, the establishment of patient support programs, the increasing adoption of telemedicine for patient management, and collaborations designed to expand access programs.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11906&type=smp

What Are The Main Drivers Boosting The Pompe Disease Industry’s Expansion?

The increasing prevalence of pompe disease is projected to propel the growth of the pompe disease market. This rare genetic disorder, also known as glycogen storage disease type II or acid maltase deficiency, is characterized by the build-up of glycogen (a complex sugar molecule) in various body tissues, especially in muscles and organs. Treatments for pompe disease include protein replacement therapy, alglucosidase alfa, and Nexviazyme for intravenous infusion. The rise in pompe disease cases is a significant factor contributing to market expansion. As an illustration, in June 2022, the European Medicines Agency Highlights, a Europe-based intergovernmental organization, noted approximately 224 infantile-onset, 471 juvenile-onset, and 20,490 adult-onset individuals in Europe with mutations that could cause Pompe disease, based on a maximum birth incidence of 11.6 per 100,000. Therefore, the heightened prevalence of pompe disease is fundamentally driving the pompe disease market’s growth.

How Is The Pompe Disease Market Classified Into Different Segments?

The pompe diseasemarket covered in this report is segmented –

1) By Type: Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form, Other Types

2) By Diagnosis: Blood Test, Genetic Test, Prenatal Test, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral, Other routes Of administrations

4) By Therapy Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Gene Therapy, Other Therapies

5) By End Users: Hospitals Or Clinics, Pharmaceuticals, Researchers, Other End-Users

Subsegments:

1) By Classic Infantile Form: Early-Onset Classic Pompe Disease; Severe Classic Pompe Disease

2) By Non-Classic Infantile Form: Mild Non-Classic Infantile Pompe Disease; Variants of Non-Classic Infantile Form

3) By Late-Onset Form: Adult-Onset Pompe Disease; Juvenile-Onset Pompe Disease

4) By Other Types: Asymptomatic Carriers; Other Rare Variants of Pompe Disease

What Trends Are Redefining The Pompe Disease Market Dynamics?

Product innovations represent a key trend gaining traction in the pompe disease market. Major companies operating within the pompe disease market are increasingly adopting these innovations to maintain their competitive standing. For instance, in September 2023, Amicus Therapeutics, a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for its Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) 65 mg capsules. This two-component therapy is specifically engineered for adults with late-onset Pompe disease (LOPD) weighing =40 kg. Pombiliti and Opfolda form a unique combination, where Pombiliti serves as a recombinant human GAA enzyme (rhGAA) designed for enhanced uptake into muscle cells, and Opfolda functions as an enzyme stabilizer to ensure the enzyme’s stability in the blood. This significant FDA approval highlights the importance of advancements in science and medicine.

Who Are The Prominent Global Companies Shaping The Pompe Disease Market?

Major companies operating in the pompe disease market include F. Hoffmann-La Roche AG, Sanofi S.A., Amicus Therapeutics Inc., Sangamo BioSciences Inc., Asklepios BioPharmaceutical Inc., Audentes Therapeutics Inc., Genethon, Maze Therapeutics Inc., Avidity Biosciences Inc., EpiVax Inc., M6P Therapeutics, Oxyrane UK Limited, Valerion Therapeutics LLC, Abeona Therapeutics Inc., BioMarin Pharmaceutical, Genzyme Corporation, Novartis AG, Ultragenyx Pharmaceutical, Aro Biotherapeutics Company, Akashi Therapeutics, Protalix BioTherapeutics, AVROBIO Inc., Catabasis Pharmaceuticals

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pompe-disease-global-market-report

What Regional Growth Trends Are Shaping The Pompe Disease Market Outlook?

North America was the largest region in the pompe disease market in 2024. The regions covered in the pompe disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Pompe Disease Market Report:

https://www.thebusinessresearchcompany.com/customise?id=11906&type=smp

Browse Through More Reports Similar to the Global Pompe Disease Market 2025, By The Business Research Company

Preventive Healthcare Technologies And Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/preventive-healthcare-technologies-and-services-global-market-report

Healthcare It Integration Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/healthcare-it-integration-global-market-report

Healthcare Interoperability Solutions Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/healthcare-interoperability-solutions-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795